EA034795B1 - Способ определения изменений фекальной микробиоты индивида после приема композиции, содержащей микроорганизмы - Google Patents

Способ определения изменений фекальной микробиоты индивида после приема композиции, содержащей микроорганизмы Download PDF

Info

Publication number
EA034795B1
EA034795B1 EA201690465A EA201690465A EA034795B1 EA 034795 B1 EA034795 B1 EA 034795B1 EA 201690465 A EA201690465 A EA 201690465A EA 201690465 A EA201690465 A EA 201690465A EA 034795 B1 EA034795 B1 EA 034795B1
Authority
EA
Eurasian Patent Office
Prior art keywords
lactobacillus
microorganisms
composition
placebo
individual
Prior art date
Application number
EA201690465A
Other languages
English (en)
Russian (ru)
Other versions
EA201690465A1 (ru
Inventor
Андреа Биффи
Руджеро Росси
Вальтер Фьоре
Симоне Доменико Гульельметти
Original Assignee
Софар С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Софар С.П.А. filed Critical Софар С.П.А.
Publication of EA201690465A1 publication Critical patent/EA201690465A1/ru
Publication of EA034795B1 publication Critical patent/EA034795B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201690465A 2013-09-06 2014-09-05 Способ определения изменений фекальной микробиоты индивида после приема композиции, содержащей микроорганизмы EA034795B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001473A ITMI20131473A1 (it) 2013-09-06 2013-09-06 Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
PCT/IB2014/064284 WO2015033304A1 (en) 2013-09-06 2014-09-05 Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota

Publications (2)

Publication Number Publication Date
EA201690465A1 EA201690465A1 (ru) 2016-08-31
EA034795B1 true EA034795B1 (ru) 2020-03-23

Family

ID=49354801

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201690465A EA034795B1 (ru) 2013-09-06 2014-09-05 Способ определения изменений фекальной микробиоты индивида после приема композиции, содержащей микроорганизмы
EA202090097A EA202090097A1 (ru) 2013-09-06 2014-09-05 Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090097A EA202090097A1 (ru) 2013-09-06 2014-09-05 Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту

Country Status (13)

Country Link
US (1) US20160348155A1 (cg-RX-API-DMAC10.html)
EP (1) EP3047032A1 (cg-RX-API-DMAC10.html)
JP (1) JP6701078B2 (cg-RX-API-DMAC10.html)
CN (1) CN105518150A (cg-RX-API-DMAC10.html)
BR (1) BR112016005064A2 (cg-RX-API-DMAC10.html)
CA (1) CA2923390A1 (cg-RX-API-DMAC10.html)
EA (2) EA034795B1 (cg-RX-API-DMAC10.html)
HK (1) HK1223982A1 (cg-RX-API-DMAC10.html)
IL (1) IL244391B (cg-RX-API-DMAC10.html)
IT (1) ITMI20131473A1 (cg-RX-API-DMAC10.html)
MX (2) MX2016002766A (cg-RX-API-DMAC10.html)
SG (1) SG11201601664VA (cg-RX-API-DMAC10.html)
WO (1) WO2015033304A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4575491A1 (en) 2023-12-22 2025-06-25 Vilnius University Method for detecting volatile organic compounds in faecal matter odour

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
CN108350508B (zh) * 2015-10-29 2021-09-17 株式会社益力多本社 雌马酚产生能力的测定方法
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) * 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
CN106318890A (zh) * 2016-10-21 2017-01-11 山东省农业科学院畜牧兽医研究所 一株分离自spf鸡嗉囊的产植酸酶卷曲乳杆菌菌株及其应用
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CN111936639A (zh) * 2018-01-17 2020-11-13 生物技术网络研究中心联合会 针对降低受试者中的循环琥珀酸盐水平的靶向干预，以及用于确定所述干预的有效性的试剂盒和方法
CN112384227A (zh) 2018-02-09 2021-02-19 N·V·努特里奇亚 含有不可消化寡糖的发酵配方物
JP2021520191A (ja) * 2018-04-02 2021-08-19 サン ジェノミクス インコーポレイテッド 試料中の１つ以上の種類の微生物の多様な集団から核酸分子を抽出するための万能な方法
CN110029155A (zh) * 2019-05-27 2019-07-19 天益健康科学研究院（镇江）有限公司 一种基于荧光定量pcr组合式肠道细菌检测方法
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
CN116287163A (zh) * 2023-02-17 2023-06-23 浙江大学 一种评估肠道菌群对菊粉的动态响应方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022727A1 (en) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Probiotic bacterium: lactobacillus fermentum
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2005001109A2 (en) * 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
WO2005083122A2 (en) * 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2006050479A2 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
CN1840206A (zh) * 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
WO2007071815A1 (en) * 2005-12-22 2007-06-28 Cyflo Oy Method for monitoring and promoting the nutrition and well-being of an animal and/or a human being as well as the productivity of animals
US20090061446A1 (en) * 2006-02-21 2009-03-05 National University Corporation University Of Toyama Method for quickly identifying pathogenic bacteria responsible for infection
US20100112564A1 (en) * 2008-02-21 2010-05-06 Shanghai Jiao Tong University Methods for detecting therapeutic effects of anti-cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010161944A (ja) * 2009-01-13 2010-07-29 Syngen Biotech Co Ltd 新型カゼイ菌の亜種（ｓｇ９６）及びこれを含有する菌抑制組成物及びその用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2004022727A1 (en) * 2002-09-06 2004-03-18 Vri Biomedical Ltd Probiotic bacterium: lactobacillus fermentum
WO2005001109A2 (en) * 2003-05-06 2005-01-06 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Methods and compositions to detect microbes in fecal samples
WO2005083122A2 (en) * 2004-02-27 2005-09-09 Stichting Laboratorium Voor Infectieziekten Method for detecting a microorganism in a fecal specimen
WO2006050479A2 (en) * 2004-11-01 2006-05-11 George Mason University Compositions and methods for diagnosing colon disorders
WO2007071815A1 (en) * 2005-12-22 2007-06-28 Cyflo Oy Method for monitoring and promoting the nutrition and well-being of an animal and/or a human being as well as the productivity of animals
CN1840206A (zh) * 2006-01-19 2006-10-04 上海交通大学 人源菌群仔猪模型的构建及仔猪肠道中菌群分子检测方法
US20090061446A1 (en) * 2006-02-21 2009-03-05 National University Corporation University Of Toyama Method for quickly identifying pathogenic bacteria responsible for infection
US20100112564A1 (en) * 2008-02-21 2010-05-06 Shanghai Jiao Tong University Methods for detecting therapeutic effects of anti-cancer drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Example Cross-Over Study Design (A Phase II, Randomized, Double-Blind Crossover Study of Hypertena and Placebo in Participants with High Blood Pressure) Methods Study Design", October 2012 (2012-10), XP055119522, Retrieved from the Internet: URL: http: //prsinfo.clinicaltrials.gov/trainTrainer/Crossover-Design-Fiction-Manuscri pt.pdf [retrieved on 2014-05-22] the whole document *
F. SAVINO, L. CORDISCO, V. TARASCO, E. PALUMERI, R. CALABRESE, R. OGGERO, S. ROOS, D. MATTEUZZI: "Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial", PEDIATRICS, AMERICAN ACADEMY OF PEDIATRICS, vol. 126, no. 3, 1 September 2010 (2010-09-01), pages e526 - e533, XP055119050, ISSN: 00314005, DOI: 10.1542/peds.2010-0433 *
PLANT, L. ET AL.: "Association of lactobacillus spp. with Peyer's Patches in Mice", CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY., AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 8, no. 2, 1 January 2001 (2001-01-01), US, pages 320 - 324, XP002990497, ISSN: 1071-412X, DOI: 10.1128/CDLI.8.2.320-324.2001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4575491A1 (en) 2023-12-22 2025-06-25 Vilnius University Method for detecting volatile organic compounds in faecal matter odour

Also Published As

Publication number Publication date
JP2016528926A (ja) 2016-09-23
CA2923390A1 (en) 2015-03-12
US20160348155A1 (en) 2016-12-01
ITMI20131473A1 (it) 2015-03-07
EP3047032A1 (en) 2016-07-27
IL244391B (en) 2021-02-28
MX2016002766A (es) 2016-08-03
WO2015033304A1 (en) 2015-03-12
IL244391A0 (en) 2016-04-21
HK1223982A1 (zh) 2017-08-11
SG11201601664VA (en) 2016-04-28
EA202090097A1 (ru) 2020-04-07
MX2022013625A (es) 2022-11-16
CN105518150A (zh) 2016-04-20
JP6701078B2 (ja) 2020-05-27
EA201690465A1 (ru) 2016-08-31
BR112016005064A2 (pt) 2017-11-21

Similar Documents

Publication Publication Date Title
JP6701078B2 (ja) 微生物を含む組成物の腸内微生物叢に対する効果の評価方法
De Filippis et al. The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health
Xiao et al. Mining Lactobacillus and Bifidobacterium for organisms with long-term gut colonization potential
US11752179B2 (en) Medical use of probiotics
Derrien et al. Fate, activity, and impact of ingested bacteria within the human gut microbiota
Unno et al. Changes in human gut microbiota influenced by probiotic fermented milk ingestion
Matijašić et al. Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: a randomized double-blind, placebo-controlled trial
Rampelli et al. A probiotics-containing biscuit modulates the intestinal microbiota in the elderly
Ringel et al. Alterations in the intestinal microbiota and functional bowel symptoms
Lebaka et al. Development of new probiotic foods—a case study on probiotic juices
AU2014316688B2 (en) Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
US12036254B2 (en) Bacterial strains of the Lactobacillus paracasei species for use, oral or topical, in the treatment of disorders of the female urogenital tract
Gerritsen The genus Romboutsia: genomic and functional characterization of novel bacteria dedicated to life in the intestinal tract
Taverniti et al. Short-term daily intake of 6 billion live probiotic cells can be insufficient in healthy adults to modulate the intestinal bifidobacteria and lactobacilli
CA3179561A1 (en) Composition for improving gut microbiota
Poutsiaka et al. Selective method for identification and quantification of Bifidobacterium animalis subspecies lactis BB‐12 (BB‐12) from the gastrointestinal tract of healthy volunteers ingesting a combination probiotic of BB‐12 and Lactobacillus rhamnosus GG
RU2546253C2 (ru) Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженной кишки с использованием этого продукта
US20210315948A1 (en) Probiotics and methods of use
AU2022228145A1 (en) Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
AU2014316687A1 (en) Method for evaluating the effects of a composition comprising microorganisms on intestinal microbiota
HK40101402A (en) New medical use of probiotics
Iqbal et al. A NOVEL PROBIOTIC BLEND FOR POTENTIAL USE IN THE METABOLIC SYNDROME: DESIGN AND IN-VITRO CHARACTERIZATIONS.
Linpisanl Detection of beneficial microbiota in mouse colon
HK40090429A (en) Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid
HK40000411A (en) New medical use of probiotics